RSR Limited is pleased to announce that ElisaRSR™ 3 Screen ICA™, a new ELISA combination assay kit which detects autoantibodies to GAD and/or IA-2 and/or ZnT8, is now available for research use only.
ElisaRSR™3 Screen ICA™ is designed as an initial screen for individuals who have or who are at risk for autoimmune diabetes.
1) ELISA Version2 compared with ELISA Version1
RSR's Version2 AQP4 Ab ELISA is more sensitive than the original Version1 assay.
For example, in a study of 62 sera from patients with NMO or NMOSD, 48 (77%) were positive for AQP4 Ab by Version2 ELISA compared to 41 (66%) being positive in the Version1 ELISA. A further study on a different group of patient sera showed 64/64 positive with the Version2 AQP4 Ab ELISA whereas 57/64 (89%) were positive with the Version1 ELISA.
The Version1 AQP4 Ab ELISA is no longer available from RSR.
2) ELISA Version2 compared with a commercially available cell based assay (CBA)
In a study of 43 NMOSD sera selected for low or undetectable levels of AQP4 Ab, 22 (51%) were positive for AQP4 Ab by RSR’s Version2 ELISA and 13/43 (30%) were positive by CBA.
The 9 samples which gave discrepant results were all positive in the ELISA but negative in the CBA.
This study indicates that RSR’s Version2 AQP4 Ab ELISA is more sensitive than the commercially available CBA.
|© 2010 - 2017 RSR Limited. All Rights Reserved|